Sector News

KU Leuven, Batavia partner to develop Covid-19 vaccine candidate

December 6, 2020
Life sciences

KU Leuven in Belgium has partnered with contract development and manufacturing organisation, Batavia Biosciences, to develop a vector-based Covid-19 vaccine candidate.

The KU Leuven Rega Institute for Medical Research Virology research team, headed by Prof Dr Johan Neyts, developed a vaccine candidate with an attenuated vector carrying the SARS-CoV-2 spike immunogen.

The vector derives from the live-attenuated yellow fever vaccine (YF17D strain).

Currently named RegaVax, the YF17D-SARS-CoV-2 vaccine candidate demonstrated convincing immunogenicity and efficacy data in pre-clinical challenge studies.

Based on data, the research team intends to progress to the next phase of development, preparation for clinical trials.

To aid this process, KU Leuven joined forces with Batavia Biosciences.

Neyts said: “RegaVax is the only Covid-19 vaccine candidate based on the yellow fever vaccine. In preclinical models, for example with hamsters, one single dose appears to be highly efficient in protecting against infection with SARS-CoV-2.

“We hope that this vaccine, will, like the yellow fever vaccine on which it is based, provide, after a single dose, long-lasting protection against this coronavirus.”

Leveraging its vaccine development and manufacturing expertise along with HIP-Vax manufacturing technology, Batavia will develop a clinical manufacturing process for RegaVax, deliver clinical product and prepare for large-scale commercial supply.

Batavia Biosciences COO Dr Christopher Yallop said: “Our HIP-Vax technology is ideally suited to develop and manufacture this vaccine rapidly and cost-effectively and we are very much looking forward to working closely with the KU Leuven team to deliver the clinical product and help move this vaccine candidate to licensure.”

KU Leuven and Batavia Biosciences plan to deliver the clinical product and initiate clinical testing next year.

by Pharmaceutical-Technology.com

Source: pharmaceutical-technology.com

comments closed

Related News

October 17, 2021

Colorcon acquires a majority share in Ideal Cures Pvt. Ltd., India

Life sciences

Ideal Cures will operate as a fully independent entity within Colorcon. Their business complements Colorcon’s position in the Indian pharmaceutical market with a strong presence in the domestic generic sector comprised of long-standing customer relationships sustained by innovative and customized solutions.

October 17, 2021

Barriers exist, but participation urgent in breast cancer clinical trials: report

Life sciences

Across four new breast cancer treatments approved by the FDA last year, 2% to 9% of patients in clinical trials for the drugs were Black Americans and 0% to 9% were Hispanic, according to a new report from Breastcancer.org.

October 17, 2021

Danish consortium acquires part of Jernbanebyen to create one of the world’s healthiest urban villages

Life sciences

The southern section of Jernbanebyen in central Copenhagen has a new owner. The Baneby Consortium, comprising NREP, Novo Holdings and Industriens Pension, has bought the land from Freja Ejendomme. The ambition is to create a green, partly car-free environment that will also be one of the healthiest in the world. 

Send this to a friend